Thornburg Investment Management Inc. lifted its position in AstraZeneca plc (NYSE:AZN) by 8.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 707,062 shares of the company’s stock after purchasing an additional 52,782 shares during the period. Thornburg Investment Management Inc.’s holdings in AstraZeneca were worth $28,587,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in AZN. FMR LLC boosted its holdings in shares of AstraZeneca by 59.6% in the fourth quarter. FMR LLC now owns 56,373,971 shares of the company’s stock valued at $2,141,084,000 after purchasing an additional 21,048,181 shares during the period. Jennison Associates LLC lifted its holdings in AstraZeneca by 15.2% during the fourth quarter. Jennison Associates LLC now owns 45,796,787 shares of the company’s stock worth $1,739,362,000 after buying an additional 6,052,483 shares during the period. Fisher Asset Management LLC lifted its holdings in AstraZeneca by 10.7% during the fourth quarter. Fisher Asset Management LLC now owns 14,965,240 shares of the company’s stock worth $568,380,000 after buying an additional 1,448,516 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in AstraZeneca by 189.5% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,231,390 shares of the company’s stock worth $46,768,000 after buying an additional 805,985 shares during the period. Finally, Bank of Montreal Can lifted its holdings in AstraZeneca by 28.9% during the first quarter. Bank of Montreal Can now owns 2,594,828 shares of the company’s stock worth $104,909,000 after buying an additional 581,139 shares during the period. Hedge funds and other institutional investors own 18.32% of the company’s stock.
Shares of AZN stock traded down $0.01 during trading hours on Friday, reaching $37.79. 41,300 shares of the company’s stock were exchanged, compared to its average volume of 5,211,315. The company has a market cap of $95.44 billion, a PE ratio of 10.90, a PEG ratio of 1.16 and a beta of 0.47. The company has a current ratio of 0.75, a quick ratio of 0.58 and a debt-to-equity ratio of 1.48. AstraZeneca plc has a fifty-two week low of $34.38 and a fifty-two week high of $43.29.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Friday, April 26th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The business had revenue of $5.47 billion for the quarter, compared to the consensus estimate of $5.40 billion. AstraZeneca had a return on equity of 37.91% and a net margin of 10.75%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.48 earnings per share. On average, equities analysts forecast that AstraZeneca plc will post 1.79 earnings per share for the current year.
A number of research firms have weighed in on AZN. Zacks Investment Research upgraded AstraZeneca from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Thursday, April 4th. Cowen upgraded AstraZeneca from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $42.00 to $48.00 in a report on Monday, April 1st. ValuEngine lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, April 1st. UBS Group lowered AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 target price for the company. in a report on Tuesday, April 2nd. Finally, BNP Paribas began coverage on AstraZeneca in a report on Tuesday, February 5th. They set an “outperform” rating for the company. Three research analysts have rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $45.29.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Fundamental Analysis – How It Helps Investors
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.